Increased risk for attacks seen in women younger than 35 years, those with eosinophilia, those with lower corticosteroid use.

Topline data were announced from two phase 3 studies evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS -mutated recurrent ...

The prescription device is a wearable belt that includes a motor designed to transmit low amplitude, high frequency vibration to the spine and hips.

The Food and Drug Administration (FDA) has cleared the Jewel ® Patch Wearable Cardioverter Defibrillator (Patch-WCD) for adult patients aged 18 years and older who are at risk for sudden cardiac ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

The Teal Wand is an at-home vaginal self-collection device intended to test for 14 types of high-risk HPV that have the ...

New epinephrine nasal spray dosage approved for pediatrics; FDA agree to review semaglutide for weight management; wearable defibrillator cleared to prevent sudden cardiac arrest; a low dose ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Introduction of pregnancy checkbox associated with increase in reported maternal mortality of 6.78 deaths per 100,000 livebirths.

Tepylute is indicated for the treatment of adenocarcinoma of the breast or ovary . It is now supplied as a multiple-dose vial ...

The approach could mean no COVID boosters will be approved in time for next winter’s respiratory disease season, Makary has warned in earlier interviews.